$BNTX · The Motley Fool · 2026-11-14
暂无中文摘要,仅英文原句可核对。
播放时,YouTube 可能接收设备与播放信息并使用 Cookie。 隐私说明 · Google 隐私政策
逐段跳播
未来对该公司及其增长故事来说将是最重要的。有意思的一点是谈谈 Billion to One 所依赖的平台技术。只是为了解释一下它为什么更有特色一些。
will be the most important to the company and its growth story in the future. One of the interesting things is to talk about the platform technology that Billion to One relies on.
Just to explain why it's a bit more distinctive.
Billion to One 平台的运作方式是给每个 DNA 分子连接一个独特的标签,使其能够真正计数这些分子,而不是估算它们的比例。你可以把它想象成称量一袋混合硬币来估算其中硬币数量,与逐一标记并清点每枚硬币之间的区别。
The Billion to One platform works by linking a unique tag to each DNA molecule, enabling it to actually count those molecules rather than estimate their proportion. You can think of it as the difference between weighing a mixed bag of coins to estimate the number of coins in it, versus marking and counting each coin individually.
正是这种精度,即单分子级别的精度,使 Billion2One 能够提供这些高度准确的诊断检测,而一些老牌竞争对手至今还无法提供。
This precision, that is, precision at the level of a single molecule, is what allows Billion2One to offer these highly accurate diagnostic tests that some established competitors have not yet been able to provide.
他们大约一周前还公布了季度业绩,总营收超出市场普遍预期约50%,同比增长。摊薄每股收益是华尔街预期的两倍多。他们的产前检测营收同比增长41%。肿瘤业务营收仍是公司较小但增长最快的部分,同比增长96%,现在年化约6800万美元。
本季度他们产生了约900万美元的自由现金流。这是他们连续第五个季度按照公认会计原则实现正营业收入。资产负债表上,他们拥有约5.62亿美元现金及现金等价物。
They also announced their quarterly results about a week ago, with total revenue exceeding consensus estimates by about 50% year-over-year. Diluted earnings per share were more than double what Wall Street had expected.
Their revenue from prenatal testing increased by 41% year-on-year. Oncology revenues, which are still a smaller but fastest-growing part of the company, have increased by 96% year-on-year, and now reach an annual rate of about $68 million.
They generated approximately $9 million in free cash flow during the quarter. This was the fifth consecutive quarter in which they achieved positive operating income according to generally accepted accounting principles.
They have approximately $562 million in cash and cash equivalents on their balance sheet.
关于他们的肿瘤业务,最值得关注的一点是他们有一项新检测将于12月中旬推出。这是一项检测微小残留病灶的检测。本质上,这项检测旨在发现患者肿瘤经手术切除后残留的微观癌症痕迹。它仅是一项基于血液的检测。
从第一天起就适用于所有实体瘤。它将在未来几周内发布。这对他们扩展肿瘤检测范围至关重要。
One of the most important things to watch regarding their oncology work is that they have a new test that will be launched in mid-December. This is a test to detect minimal residual disease.
Essentially, this test is designed to detect microscopic traces of cancer that remain after a patient's tumor has been surgically removed. It is a blood-based test only. It is available for all solid tumors from day one.
It will be released here in the next few weeks. This is essential as they work to expand their range of tumor tests.
这是一项很棒的业务。这是一项赚钱的业务。这是一项在产前检测和肿瘤业务上都持续实现非常强劲增长的业务。但对我来说,他们将这些高端癌症监测产品推向一个广阔、可及的市场——管理层估计该市场价值约300亿美元——是在这个已经得到验证的技术平台之外的额外亮点。
我认为 Billion to One 还有很长的增长路要走,我认为这绝对是一项值得在2026年底之前列入观察名单的业务。
It's a great job. It's a profitable business. It is a business that continues to see very strong growth across both its prenatal testing and oncology businesses. But for me, the fact that they are launching these premium cancer monitoring products into a broad, accessible market— which the administration estimates to be worth about $30 billion—is in addition to this already validated technology platform.
I think Billion to One has a long way to go to grow, and I think this is definitely a business to put on your watchlist before the end of 2026.